Bank of Nova Scotia’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bank of Nova Scotia’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,400	Closed	-$1.5M	–	1137
2025 Q1	$1.5M	Buy	+11,400	New	+$1.42M	﹤0.01%	677
2024 Q4	–	Sell	-49,000	Closed	-$3.59M	–	1137
2024 Q3	$3.59M	Buy	+49,000	New	+$3.68M	0.01%	532

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bank of Nova Scotia's ITCI Position: Q2 2025 in Review

Bank of Nova Scotia sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 11,400 shares — an estimated $1.5M sold.

Bank of Nova Scotia first reported a position in ITCI in Q3 2024 and held it in 2 quarters. The position peaked at $3.59M in Q3 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Bank of Nova Scotia reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Bank of Nova Scotia sold 11,400 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $1.5M.
Bank of Nova Scotia first reported a position in Intra-Cellular Therapies Inc. in Q3 2024 and held it in 2 quarters.
Bank of Nova Scotia's Intra-Cellular Therapies Inc. position peaked at $3.59M in Q3 2024.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Bank of Nova Scotia's 13F filing for Q2 2025, filed 13 Aug 2025.